TapewireFind a company

person · Reporting owner

Grimes Scott D.

Disclosed activity across 4 companies

Tapewire entity
122482
SEC CIK
0001617486

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Cardlytics, Inc.CDLX · Entity 7603DirectorNovember 08, 2022November 10, 2022
Evergy, Inc.EVRG · Entity 3282DirectorApril 01, 2020April 02, 2020
Plum Acquisition Corp. IIIAPTMU · Entity 83854DirectorJuly 27, 2021July 27, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cardlytics, Inc.

Report date November 08, 2022 · Filed November 10, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect248,779 Reported balance After 2022-11-08 transaction · row 1
1 source row

Row 1 · 2022-11-08 · Sale · Disposed 6 · Balance 248,779

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.

Common StockSEC Table I · non-derivativeIndirectSee Footnote55,832 Reported balance Holding disclosure · report date 2022-11-08 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 55,832

F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.

Common StockSEC Table I · non-derivativeIndirectSee Footnote53,112 Reported balance Holding disclosure · report date 2022-11-08 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 53,112

F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.

F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.

F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.

Evergy, Inc.

Report date April 01, 2020 · Filed April 02, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Deferred Share UnitsSEC Table II · derivative / convertible securityDirect13,666 Reported balance After 2020-04-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-04-01 · Grant · Acquired 455 · Balance 13,666

F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.

Common StockSEC Table I · non-derivativeDirect788 Reported balance Holding disclosure · report date 2020-04-01 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 788

Filing footnotes · ownership attribution and instrument terms

F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.

Plum Acquisition Corp. III

Report date July 27, 2021 · Filed July 27, 2021

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GREAT PLAINS ENERGY INC

Report date June 04, 2018 · Filed June 05, 2018

Section 16 reporting ended · disclosed 2018-06-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-06-04 transaction · row 1
1 source row

Row 1 · 2018-06-04 · Disposition to issuer · Disposed 1,318 · Balance 0

F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.

Director Deferred Share UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2018-06-04 · Disposition to issuer · Disposed 11,970 · Balance 0

F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.

F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2020 Filed May 23, 2020 01:29 UTC Cardlytics, Inc. CDLX · Entity 7603 GrantRestricted Stock Units · Derivative 355 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000149 · wf-form4_159019734968767.xml · derivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 355

Underlying: Common Stock · 355 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

F5 · derivative.exercise_date: The RSUs are immediately vested.

F5 · derivative.expiration_date: The RSUs are immediately vested.

Read SEC document
May 20, 2020 Filed May 23, 2020 01:29 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 355 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000149 · wf-form4_159019734968767.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 289 shares of Common Stock acquired under the Issuer's Employee Stock Purchase Plan.

Read SEC document
May 19, 2020 Filed May 20, 2020 21:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,000 $60.00 $120,000.00
Disclosure

SEC source: 0001666071-20-000135 · wf-form4_159000892266350.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 129,112

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
May 12, 2020 Filed May 13, 2020 20:22 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 6,000 $60.00 $360,000.00
Disclosure

SEC source: 0001666071-20-000130 · wf-form4_158940136087784.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 131,112

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
May 12, 2020 Filed May 13, 2020 20:22 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 15,000 $60.00 $900,000.00
Disclosure

SEC source: 0001666071-20-000130 · wf-form4_158940136087784.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,431

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

Read SEC document
April 22, 2020 Filed Apr 23, 2020 20:15 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 22,372 $40.98 $916,804.56
Disclosure

SEC source: 0001666071-20-000121 · wf-form4_158767288897808.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,431

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $40.60 to $41.59, inclusive.

Read SEC document
April 22, 2020 Filed Apr 23, 2020 20:15 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 15,128 $40.16 $607,540.48
Disclosure

SEC source: 0001666071-20-000121 · wf-form4_158767288897808.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,803

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
April 21, 2020 Filed Apr 22, 2020 20:18 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,100 $41.46 $128,526.00
Disclosure

SEC source: 0001666071-20-000120 · wf-form4_158758669544897.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,931

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.84, inclusive.

Read SEC document
April 21, 2020 Filed Apr 22, 2020 20:18 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 8,888 $40.25 $357,742.00
Disclosure

SEC source: 0001666071-20-000120 · wf-form4_158758669544897.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,031

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $40.05 to $41.04, inclusive.

Read SEC document
April 21, 2020 Filed Apr 22, 2020 20:18 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 22,812 $39.75 $906,777.00
Disclosure

SEC source: 0001666071-20-000120 · wf-form4_158758669544897.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,919

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.01, inclusive.

Read SEC document
April 21, 2020 Filed Apr 22, 2020 20:18 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,700 $38.57 $104,139.00
Disclosure

SEC source: 0001666071-20-000120 · wf-form4_158758669544897.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301,731

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $38.01 to $38.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

Read SEC document
April 16, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 400 $44.30 $17,720.00
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 6

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,431

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $44.29 to $44.32, inclusive.

Read SEC document
April 16, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 16,194 $43.88 $710,592.72
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,831

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.15, inclusive.

Read SEC document
April 16, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 20,906 $42.79 $894,567.74
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,025

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $42.29 to $43.28, inclusive.

Read SEC document
April 15, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,468 $44.06 $108,740.08
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,931

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.33, inclusive.

Read SEC document
April 15, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 25,656 $43.45 $1,114,753.20
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,399

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $43.01 to $44.00, inclusive.

Read SEC document
April 15, 2020 Filed Apr 17, 2020 20:09 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 9,376 $42.68 $400,167.68
Disclosure

SEC source: 0001666071-20-000110 · wf-form4_158715418020756.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 370,055

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $42.01 to $43.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

Read SEC document
April 01, 2020 Filed Apr 2, 2020 21:28 UTC Evergy, Inc. EVRG · Entity 3282 GrantDirector Deferred Share Units · Derivative 455 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-012811 · form4.xml · derivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,666

Underlying: Common Stock · 455 shares

Expires not disclosed

F1 · derivative.exercise_price: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2 · kind: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F2 · derivative.exercise_date: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F2 · derivative.expiration_date: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3 · balance_after: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.

Read SEC document
April 01, 2020 Filed Apr 14, 2020 00:55 UTC Cardlytics, Inc. CDLX · Entity 7603 GrantRestricted Stock Unit · Derivative 59,678 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000105 · wf-form4_158682568993889.xml · derivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,678

Underlying: Common Stock · 59,678 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

F2 · derivative.exercise_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date.

F2 · derivative.expiration_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date.

Read SEC document
March 25, 2020 Filed Mar 27, 2020 20:32 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 600 $43.89 $26,334.00
Disclosure

SEC source: 0001666071-20-000091 · wf-form4_158534115925982.xml · nonDerivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,431

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $43.45 to $44.24, inclusive.

Read SEC document
March 25, 2020 Filed Mar 27, 2020 20:32 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,640 $42.60 $155,064.00
Disclosure

SEC source: 0001666071-20-000091 · wf-form4_158534115925982.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,031

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $42.23 to $43.02, inclusive.

Read SEC document
March 25, 2020 Filed Mar 27, 2020 20:32 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,860 $41.69 $119,233.40
Disclosure

SEC source: 0001666071-20-000091 · wf-form4_158534115925982.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,671

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.03, inclusive.

Read SEC document
March 25, 2020 Filed Mar 27, 2020 20:32 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,100 $40.50 $44,550.00
Disclosure

SEC source: 0001666071-20-000091 · wf-form4_158534115925982.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,531

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive.

Read SEC document
March 25, 2020 Filed Mar 27, 2020 20:32 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,800 $39.46 $71,028.00
Disclosure

SEC source: 0001666071-20-000091 · wf-form4_158534115925982.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,631

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.

Read SEC document
March 23, 2020 Filed Mar 25, 2020 20:26 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $30.52 $30,520.00
Disclosure

SEC source: 0001666071-20-000089 · wf-form4_158516800148825.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 137,112

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
March 09, 2020 Filed Mar 11, 2020 23:20 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $42.07 $42,070.00
Disclosure

SEC source: 0001666071-20-000077 · wf-form4_158396880794799.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,112

F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F5 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
March 09, 2020 Filed Mar 11, 2020 23:20 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 300 $43.95 $13,185.00
Disclosure

SEC source: 0001666071-20-000077 · wf-form4_158396880794799.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,431

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on February 26, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $43.91 to $44.03, inclusive.

Read SEC document
March 09, 2020 Filed Mar 11, 2020 23:20 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 7,160 $43.31 $310,099.60
Disclosure

SEC source: 0001666071-20-000077 · wf-form4_158396880794799.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,731

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on February 26, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $42.86 to $43.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 26, 2020 Filed Mar 3, 2020 00:33 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionPerformance Stock Unit · Derivative 19,688 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000044 · wf-form4_158319561101694.xml · derivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,062

Underlying: Common Stock · 19,688 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on February 26, 2020, 6 months after the Certification, and have not yet been delivered. The final twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification.

F4 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on February 26, 2020, 6 months after the Certification, and have not yet been delivered. The final twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification.

Read SEC document
February 26, 2020 Filed Mar 3, 2020 00:33 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 19,688 Not disclosed Not disclosed
Disclosure

SEC source: 0001666071-20-000044 · wf-form4_158319561101694.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,891

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the underlying vested shares which have not been delivered.

F2 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $92.56 $18,512.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 10

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,203

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F12 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $92.40 to $92.71, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $91.36 $9,136.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 9

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,403

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F11 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $91.36 to $91.47, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $90.17 $18,034.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 8

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,503

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F10 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $89.96 to $90.37, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,000 $89.23 $178,460.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 7

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,703

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F9 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $88.88 to $89.86, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,803 $88.49 $248,037.47
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 6

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,703

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F8 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $87.83 to $88.80, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $87.13 $17,426.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 382,506

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.75 to $87.505, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 581 $85.47 $49,658.07
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 382,706

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.19 to $85.69, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,116 $84.60 $263,613.60
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,287

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.14 to $84.93, inclusive.

Read SEC document
February 25, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 800 $83.44 $66,752.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,403

F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.12 to $83.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (5), (6), (7), (8), (9), (10), (11) and (12) to this Form 4.

Read SEC document
February 24, 2020 Filed Feb 26, 2020 11:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $90.00 $90,000.00
Disclosure

SEC source: 0001666071-20-000035 · wf-form4_158271545339755.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 139,112

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:03 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $93.58 $93,580.00
Disclosure

SEC source: 0001666071-20-000025 · wf-form4_158154138864628.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 140,112

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 300 $87.86 $26,358.00
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 7

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,203

F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F9 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $87.79 to $87.99, inclusive.

Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,092 $87.14 $95,156.88
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 6

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,503

F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F8 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.67 to $87.64, inclusive.

Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,900 $86.04 $163,476.00
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,595

F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.66 to $86.60, inclusive.

Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,900 $85.21 $332,319.00
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,495

F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.66 to $85.65, inclusive.

Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,808 $83.98 $235,815.84
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,395

F4 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.60 to $84.32, inclusive.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $87.24 $8,724.00
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 141,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 23:11 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 900 $86.14 $77,526.00
Disclosure

SEC source: 0001666071-20-000016 · wf-form4_158016666633794.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 141,212

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.75 to $86.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6), (7), (8) and (9) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:41 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $66.61 $66,610.00
Disclosure

SEC source: 0001666071-20-000005 · wf-form4_157851970093830.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 142,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustees of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.

F2 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
January 02, 2020 Filed Jan 6, 2020 22:07 UTC Evergy, Inc. EVRG · Entity 3282 GrantDirector Deferred Share Units · Derivative 2,383 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-001178 · form4.xml · derivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,089

Underlying: Common Stock · 2,383 shares

Expires not disclosed

F1 · derivative.exercise_price: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2 · kind: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F2 · derivative.exercise_date: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F2 · derivative.expiration_date: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3 · balance_after: Includes 328 deferred share units acquired through the reinvestment of dividend equivalents.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.